Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

71.99
Delayed Data
As of 3:59pm ET
 -6.37 / -8.13%
Today’s Change
46.52
Today|||52-Week Range
91.35
+2.39%
Year-to-Date
Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study
10:17am / Zacks.com - Paid Partner Content
Biotech Premarket Movers: Insys, Ultragenyx, Alexion
9:42am / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close78.36
Today’s open73.00
Day’s range70.51 - 73.88
Volume2,164,045
Average volume (3 months)502,263
Market cap$3.3B
Dividend yield--
Data as of 3:59pm ET, 03/23/2017

Growth & Valuation

Earnings growth (last year)-56.82%
Earnings growth (this year)-14.77%
Earnings growth (next 5 years)+15.49%
Revenue growth (last year)--
P/E ratioNM
Price/Sales20,927.50
Price/Book6.82

Competitors

 Today’s
change
Today’s
% change
CTLTCatalent Inc-0.19-0.67%
GWPHGW Pharmaceuticals P...+1.62+1.36%
CLVSClovis Oncology Inc+1.35+2.01%
MDCOMedicines Co+0.34+0.68%
Data as of 4:01pm ET, 03/23/2017

Financials

Next reporting dateMay 15, 2017
EPS forecast (this quarter)-$1.73
Annual revenue (last year)$133.0K
Annual profit (last year)-$245.9M
Net profit margin-184,867.67%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Emil D. Kakkis
CFO, Senior VP &
Head-Investor Relations
Shalini Sharp
Corporate headquarters
Novato, California

Forecasts


Search for Jobs